These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31907322)

  • 61. Principles of Reconstructing the Subclonal Architecture of Cancers.
    Dentro SC; Wedge DC; Van Loo P
    Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28270531
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Prevention of cancer and the dose-effect relationship: the carcinogenic effects of ionizing radiations].
    Tubiana M
    Cancer Radiother; 2009 Jul; 13(4):238-58. PubMed ID: 19539515
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Current topics in mutations in the cancer genome].
    Iwaya T; Mimori K; Wakabayashi G
    Nihon Geka Gakkai Zasshi; 2012 Mar; 113(2):185-90. PubMed ID: 22582578
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
    Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
    J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An evolutionary perspective on chronic myelomonocytic leukemia.
    Itzykson R; Solary E
    Leukemia; 2013 Jul; 27(7):1441-50. PubMed ID: 23558522
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
    Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
    Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Should tissue structure suppress or amplify selection to minimize cancer risk?
    Hindersin L; Werner B; Dingli D; Traulsen A
    Biol Direct; 2016 Aug; 11(1):41. PubMed ID: 27549612
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.
    Zhang J; Fleischman AG; Wodarz D; Komarova NL
    J Theor Biol; 2017 Jul; 425():43-52. PubMed ID: 28501635
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Stochastic dynamics of cancer initiation.
    Foo J; Leder K; Michor F
    Phys Biol; 2011 Feb; 8(1):015002. PubMed ID: 21301064
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficient simulation under a population genetics model of carcinogenesis.
    Zhu T; Hu Y; Ma ZM; Zhang DX; Li T; Yang Z
    Bioinformatics; 2011 Mar; 27(6):837-43. PubMed ID: 21247938
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Age-related somatic mutations in the cancer genome.
    Milholland B; Auton A; Suh Y; Vijg J
    Oncotarget; 2015 Sep; 6(28):24627-35. PubMed ID: 26384365
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations.
    Rozhok AI; DeGregori J
    Proc Natl Acad Sci U S A; 2015 Jul; 112(29):8914-21. PubMed ID: 26195756
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Speculations on the roles of RB1 in tissue-specific differentiation, tumor initiation, and tumor progression.
    Hamel PA; Phillips RA; Muncaster M; Gallie BL
    FASEB J; 1993 Jul; 7(10):846-54. PubMed ID: 8344484
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer.
    Velcheti V; Radivoyevitch T; Saunthararajah Y
    Am Soc Clin Oncol Educ Book; 2017; 37():812-824. PubMed ID: 28561650
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cancer genetics: a primer for surgeons.
    Benson JR; Liau SS
    Surg Clin North Am; 2008 Aug; 88(4):681-704, v. PubMed ID: 18672136
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Signalling architectures can prevent cancer evolution.
    Oña L; Lachmann M
    Sci Rep; 2020 Jan; 10(1):674. PubMed ID: 31959809
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tumours and tissues: similar homeostatic systems?
    Demicheli R
    Target Oncol; 2013 Jun; 8(2):97-105. PubMed ID: 23636780
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Quantification of the Selective Advantage of Driver Mutations Is Dependent on the Underlying Model and Stage of Tumor Evolution.
    Bozic I
    Cancer Res; 2022 Jan; 82(1):21-24. PubMed ID: 34983781
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The (r)evolution of cancer genetics.
    Ciccarelli FD
    BMC Biol; 2010 Jun; 8():74. PubMed ID: 20594288
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Somatic mutation accumulation seen through a single-molecule lens.
    Luquette LJ; Park PJ
    Cell Res; 2021 Sep; 31(9):949-950. PubMed ID: 34316001
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.